Clinical Trial Update: Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy [Phase 3]

View source ↗

Summary

Phase 3 clinical study evaluating mavacamten (MYK-461) in adults with symptomatic obstructive hypertrophic cardiomyopathy has completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obstructive Hypertrophic Cardiomyopathy

Drugs mentioned

• Mavacamten (mavacamten)

Snippet

Sponsor: MyoKardia, Inc. | Conditions: Obstructive Hypertrophic Cardiomyopathy | Phase 3 | Status: COMPLETED | Results posted: 2021-10-04